

AD/PD™ 2021

March 9-14, 2021

Virtual Conference

AD/PD™ 2021
THE 15TH INTERNATIONAL CONFERENCE
ON ALZHEIMER'S & PARKINSON'S DISEASES
March 9-14, 2021
Virtual Conference

LEGEND:		The Conference is taking place in Central European Time - Barcelona					
PRE CONFERENCE SYMPOSIUM (Session has both pre-recorded talks + Live QA)	INDUSTRY (Exact session format will be indicated in the program)	PLENARY LECTURE (Schedule On-Demand. Will first play at the scheduled date and time and thereafter be fully on-demand)	FORUM DISCUSSION	ON-DEMAND SYMPOSIA	SYMPOSIA DISCUSSION	MEET THE PROFESSOR	
Please refer to the Conference Calendar for the Full Session details							
TUESDAY, MARCH 9, 2021							
10:00-18:40	COMMON FEATURES OF NEURODEGENERATIVE DISEASE: EXPLORING THE BRAIN-EYE CONNECTION AND BEYOND (10:00 - 17:30)	PROTECTIVE EFFECTS OF INSULIN AND INCRETINS IN AD/PD (13:30 - 18:40)					
WEDNESDAY, MARCH 10, 2021							
07:00 - 07:30	THE UNIFYING ROLE OF INNATE IMMUNITY IN THE ETIOLOGY AND PATHOGENESIS OF ALZHEIMER'S DISEASE						
07:30 - 08:00	UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY						
08:00 - 10:00		MRI 1	CONGOPHILIC AMYLOID ANGIOPATHY (CAA), VASCULAR DEMENTIA	VIRUS IMPACT ON NEURODEGENERATIVE DISEASES, HERPES SIMPLEX VIRUS, COVID-19	NEUROPATHOLOGY IN AD, LBD AND OTHER DEMENTIA		
10:00 - 12:00		IMAGING AND FLUID BIOMARKERS	EHOLINERGIC MECHANISMS IN AD AND PD	BETA STRUCTURE, TOXICITY AND NEURODEGENERATION	AUTOPHAGY		
12:00 - 14:00		FLUID BIOMARKERS 1	BLOOD-BRAIN BARRIER, VASCULAR DAMAGE IN DEMENTIA	BACE-1, PRESENILIN, GAMMA-SECRETASE AND APP PROCESSING	TRANSLATIONAL TREATMENT STRATEGIES 1	DISEASE MODELLING WITH HUMAN CELLS -TREATMENT STRATEGIES	ABETA TARGETING THERAPIES IN AD 1
15:00 - 15:30		MRI 1 Discussion	CONGOPHILIC AMYLOID ANGIOPATHY (CAA), VASCULAR DEMENTIA Discussion	VIRUS IMPACT ON NEURODEGENERATIVE DISEASES, HERPES SIMPLEX VIRUS, COVID-19 Discussion	NEUROPATHOLOGY IN AD, LBD AND OTHER DEMENTIA Discussion	EDUCATION THEATER (NONE CME/CPD CREDIT)	
15:30 - 16:00	Break						
16:00 - 16:30		IMAGING AND FLUID BIOMARKERS Discussion	EHOLINERGIC MECHANISMS IN AD AND PD Discussion	BETA STRUCTURE, TOXICITY AND NEURODEGENERATION Discussion	AUTOPHAGY Discussion		
16:30 - 17:00	Break						GUOJUN BU (16:30 - 17:30)
17:00 - 17:30		FLUID BIOMARKERS 1 Discussion	BLOOD-BRAIN BARRIER, VASCULAR DAMAGE IN DEMENTIA Discussion	BACE-1, PRESENILIN, GAMMA-SECRETASE AND APP PROCESSING Discussion	TRANSLATIONAL TREATMENT STRATEGIES 1 Discussion	DISEASE MODELLING WITH HUMAN CELLS -TREATMENT STRATEGIES Discussion	ABETA TARGETING THERAPIES IN AD 1 Discussion
17:30 - 18:00	Break						
18:00 - 19:00	FORUM ON IMPACT OF COVID-19 ON NEURODEGENERATIVE DISEASES						
19:00 - 19:30	Break						
19:30 - 20:30	FORUM ON APPLICATIONS OF NEUROPSYCHOLOGY, PET, MRI, EEG, AND CSF FOR DIAGNOSIS AND ASSESSMENT OF TREATMENT EFFECTS						

AD/PD™ 2021

March 9-14, 2021

Virtual Conference

AD/PD™ 2021

THE 15TH INTERNATIONAL CONFERENCE
ON ALZHEIMER'S & PARKINSON'S DISEASES

March 9-14, 2021

Virtual
Conference

THURSDAY, MARCH 11, 2021							
07:30 - 08:00	TBA						
08:00 - 10:00		TREATMENT STRATEGIES FOR PD AND DLB	TREM2, MICROGLIA	AD DIAGNOSIS, EARLY PHASE AD, CLINICAL TRIALS 1	TAU-TARGETED TREATMENT STRATEGIES		
10:00 - 12:00	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	IMAGING AND BIOMARKERS IN PD, LBD	ALPHA-SYNUCLEIN AND DISEASE MECHANISMS 1	TDP-43 IN ALS AND FTD	SYNAPTIC DAMAGE AND NEURONAL PLASTICITY		
12:00 - 14:00		TAU PATHOLOGY AND THERAPEUTIC STRATEGIES 1	GENETICS OF NEURODEGENERATION 1	C9ORF72 AND PROGRANULIN IN ALS AND FTD	TREM2 AND TREM 1	ORGANOIDS AND ANIMAL MODELS IN AD, PD	
14:00 - 15:30	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)						
15:30 - 16:00		TREATMENT STRATEGIES FOR PD AND DLB Discussion	TREM2, MICROGLIA Discussion	AD DIAGNOSIS, EARLY PHASE AD, CLINICAL TRIALS 1 Discussion	TAU-TARGETED TREATMENT STRATEGIES Discussion		RUDOLPH TANZI (15:00 - 16:00)
16:00 - 16:30		Break					
16:30 - 17:00	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	IMAGING AND BIOMARKERS IN PD, LBD Discussion	ALPHA-SYNUCLEIN AND DISEASE MECHANISMS 1 Discussion	TDP-43 IN ALS AND FTD Discussion	SYNAPTIC DAMAGE AND NEURONAL PLASTICITY Discussion		
17:00 - 17:30		Break					
17:30 - 18:00		TAU PATHOLOGY AND THERAPEUTIC STRATEGIES 1 Discussion	GENETICS OF NEURODEGENERATION 1 Discussion	C9ORF72 AND PROGRANULIN IN ALS AND FTD Discussion	TREM2 AND TREM 1 Discussion	ORGANOIDS AND ANIMAL MODELS IN AD, PD Discussion	
18:00 - 18:30		Break					
18:30 - 19:30	FORUM ON PHASE I-II CLINICAL TRIALS IN ALZHEIMER'S DISEASE						

AD/PD™ 2021

March 9-14, 2021

Virtual Conference

AD/PD™ 2021

THE 15TH INTERNATIONAL CONFERENCE
ON ALZHEIMER'S & PARKINSON'S DISEASES

March 9-14, 2021

Virtual
Conference

FRIDAY, MARCH 12, 2021							
07:30 - 08:00	APOE AND TREM2: ZOOMING IN ON CONVERGING MICROGLIAL RESPONSES IN ALZHEIMER'S DISEASE						
08:00 - 10:00	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT) (08:00 - 09:00)	AMYLOID AND TAU PET IMAGING	AD DIAGNOSIS, EARLY PHASE AD, CLINICAL TRIALS 2	RNA	AD ANIMAL MODELS AND MECHANISTIC ASPECTS 1		
10:00 - 12:00	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	METABOLIC PATTERNS AND CHANGES IN AD AND LBD	MOLECULAR MECHANISMS IN PROTEINOPATHY	TAU PROPAGATION AND CELLULAR INTERACTIONS	AMYLOID, TAU AND SYNAPSE PET IMAGING	GENETICS OF NEURODEGENERATION 2	
12:00 - 14:00	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT) (12:00 - 13:00)	NEUROINFLAMMATION, MICROGLIA AND ASTROCYTES	COGNITIVE DYSFUNCTIONS, PATHOLOGY AND TREATMENT APPROACHES IN PD, HD	MRI 2	BIOMARKERS, IMAGING IN AD, PD AND LBD	PATHWAYS AND TARGETS IN MODELS OF SEEDED AGGREGATION	
14:00 - 15:30	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT) (14:00-15:00)						
15:30 - 16:00		AMYLOID AND TAU PET IMAGING Discussion	AD DIAGNOSIS, EARLY PHASE AD, CLINICAL TRIALS 2 Discussion	RNA Discussion	AD ANIMAL MODELS AND MECHANISTIC ASPECTS 1 Discussion		
16:00 - 16:30	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	Break					
16:30 - 17:00		METABOLIC PATTERNS AND CHANGES IN AD AND LBD Discussion	MOLECULAR MECHANISMS IN PROTEINOPATHY Discussion	TAU PROPAGATION AND CELLULAR INTERACTIONS Discussion	AMYLOID, TAU AND SYNAPSE PET IMAGING Discussion	GENETICS OF NEURODEGENERATION 2 Discussion	CHRISTIAN HAAS (16:30 - 17:30) ANGELA GENGE (16:30 - 17:30)
17:00 - 17:30		Break					
17:30 - 18:00		NEUROINFLAMMATION, MICROGLIA AND ASTROCYTES Discussion	COGNITIVE DYSFUNCTIONS, PATHOLOGY AND TREATMENT APPROACHES IN PD, HD Discussion	MRI 2 Discussion	BIOMARKERS, IMAGING IN AD, PD AND LBD Discussion	PATHWAYS AND TARGETS IN MODELS OF SEEDED AGGREGATION Discussion	
18:00 - 18:30		Break					
18:30 - 19:30	FORUM ON TRANSLATIONAL DRUG DISCOVERY IN PD/ LBD PHASE I-III – RECENT UPDATES						

AD/PD™ 2021

March 9-14, 2021

Virtual Conference



SATURDAY, MARCH 13, 2021							
07:30 - 08:00	NEW INITIATIVES IN DRUG DEVELOPMENT FOR ALS						
08:00 - 10:00		BRAIN GUT INTERACTIONS	FLUID BIOMARKERS 2 Discussion	AD ANIMAL MODELS AND MECHANISTIC ASPECTS 2	SLEEP	EKG AND ELECTROPHYSIOLOGY	
10:00 - 12:00		AD TREATMENT STRATEGIES	TAU PATHOPHYSIOLOGY	FTD, ALS, CORTICOBASAL DEGENERATION	APOE MECHANISMS AND TREATMENT STRATEGIES	DISEASE MECHANISMS, PATHOPHYSIOLOGY: ASTROCYTES, NEUROINFLAMMATION, MICROGLIA	
12:00 - 14:00		ABETA TARGETING THERAPIES IN AD 2	DIAGNOSTICS, BIOMARKERS, IMAGING IN AD, PD AND LBD 1	PD ANIMAL MODELS, MECHANISTIC ASPECTS AND THERAPEUTIC STRATEGIES	APOE: MECHANISMS	EPIDEMIOLOGY AND GENETICS OF NEURODEGENERATION	
14:00 - 15:30	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)						
15:30 - 16:00		BRAIN GUT INTERACTIONS Discussion	FLUID BIOMARKERS 2 Discussion	AD ANIMAL MODELS AND MECHANISTIC ASPECTS 2 Discussion	SLEEP Discussion	EKG AND ELECTROPHYSIOLOGY Discussion	JIE SHEN (15:00 - 16:00) TAYLOR SCHMITZ (15:00 - 16:00)
16:00 - 16:30		Break					
16:30 - 17:00		AD TREATMENT STRATEGIES Discussion	TAU PATHOPHYSIOLOGY Discussion	FTD, ALS, CORTICOBASAL DEGENERATION Discussion	APOE MECHANISMS AND TREATMENT STRATEGIES Discussion	DISEASE MECHANISMS, PATHOPHYSIOLOGY: ASTROCYTES, NEUROINFLAMMATION, MICROGLIA Discussion	CYNTHIA LEMERE (16:30 - 17:30)
17:00 - 17:30		Break					
17:30 - 18:00		ABETA TARGETING THERAPIES IN AD 2 Discussion	DIAGNOSTICS, BIOMARKERS, IMAGING IN AD, PD AND LBD 1 Discussion	PD ANIMAL MODELS, MECHANISTIC ASPECTS AND THERAPEUTIC STRATEGIES Discussion	APOE: MECHANISMS Discussion	EPIDEMIOLOGY AND GENETICS OF NEURODEGENERATION Discussion	
18:00 - 18:30		Break					
18:30 - 19:30	FORUM ON PHASE III CLINICAL TRIALS IN ALZHEIMER'S DISEASE						

AD/PD™ 2021

March 9-14, 2021

Virtual Conference



SUNDAY, MARCH 14, 2021							
07:30 - 08:00	NONINVASIVE SENSORY STIMULATION TO TREAT ALZHEIMER'S DISEASE						
08:00 - 10:00		NON-PHARMACOLOGICAL INTERVENTIONS, IN NEURODEGENERATIVE DISEASES AND MOTOR RESERVE	SEX AND GENDER IN NEURODEGENERATIVE DISEASES	GLUCOCEREBROSIDASE, LRRK2-PD AND ALPHA-SYNUCLEIN	CLINICAL FEATURES OF AD, CORTICAL ATROPHY, DOWN SYNDROME, SPINOCEREBELLAR ATAXIAS (SCA)	AD: MITOCHONDRIA	
10:00 - 12:00		PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TREATMENTS IN NEURODEGENERATIVE DISEASES	DISEASE MECHANISMS, INFLAMMATION. MICROGLIA, ASTROCYTES, AMYLOIDS	DISEASE MECHANISMS, PATHOPHYSIOLOGY, LARKK.2 PARKIN. ALPHA -SYNUCLEIN	PD, ALS, DOWN SYNDROME: MITOCHONDRIA	TRANSLATIONAL TREATMENT STRATEGIES 2	
12:00 - 14:00		DISEASE MECHANISMS, INFLAMMATION. MICROGLIA, AMYLOIDS	DIGITAL END-POINTS AND ARTIFICIAL INTELLIGENCE	GENETICS AND EPIGENETICS OF NEURODEGENERATION	DIAGNOSTICS, BIOMARKERS, IMAGING IN AD, PD AND LBD 2	DISEASE MECHANISMS: ALPHA-SYNUCLEIN, DOPAMINERGIC DYSFUNCTION, AUTOPHAGY, NEUROTOXICITY	
14:00 - 15:30	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)						
15:30 - 16:00		NON-PHARMACOLOGICAL INTERVENTIONS, IN NEURODEGENERATIVE DISEASES AND MOTOR RESERVE Discussion	SEX AND GENDER IN NEURODEGENERATIVE DISEASES Discussion	GLUCOCEREBROSIDASE, LRRK2-PD AND ALPHA-SYNUCLEIN Discussion	CLINICAL FEATURES OF AD, CORTICAL ATROPHY, DOWN SYNDROME, SPINOCEREBELLAR ATAXIAS (SCA) Discussion	AD: MITOCHONDRIA Discussion	FRANK LAFERLA (15:30 - 16:30) KAREN ASHE (15:30 - 16:15)
16:00 - 16:30		Break					
16:30 - 17:00		PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TREATMENTS IN NEURODEGENERATIVE DISEASES Discussion	DISEASE MECHANISMS, INFLAMMATION. MICROGLIA, ASTROCYTES, AMYLOIDS Discussion	DISEASE MECHANISMS, PATHOPHYSIOLOGY, LARKK.2 PARKIN. ALPHA -SYNUCLEIN Discussion	PD, ALS, DOWN SYNDROME: MITOCHONDRIA Discussion	TRANSLATIONAL TREATMENT STRATEGIES 2 Discussion	
17:00 - 17:30	Break						
17:30 - 18:00		DISEASE MECHANISMS, INFLAMMATION. MICROGLIA, AMYLOIDS Discussion	DIGITAL END-POINTS AND ARTIFICIAL INTELLIGENCE Discussion	GENETICS AND EPIGENETICS OF NEURODEGENERATION Discussion	DIAGNOSTICS, BIOMARKERS, IMAGING IN AD, PD AND LBD 2 Discussion	DISEASE MECHANISMS: ALPHA-SYNUCLEIN, DOPAMINERGIC DYSFUNCTION, AUTOPHAGY, NEUROTOXICITY Discussion	